Abstract
Editorial.
Highlights
Nicol Keith1 and Claude Bagnis2 1Cancer Research UK Department of Medical Oncology, University of Glasgow, UK 2Department of Cellular and Gene Therapy, EFS Alpes Mediterranee, 13009 Marseille, Cedex 5, France. Going both from the organism to the DNA and from the DNA to the organism, the biology of the 20th century has paved the way for a new type of biologist who has emerged from the laboratory during the last two decades: the gene therapist
At the beginning of the nineties, much of this young field was based on a relatively simple concept: a deficient function can be replaced with an artificial gene
According to the increasing numbers of papers published which relate to gene therapy, and the huge interest generated by meetings of the American or the European Society of Gene Therapy, we are certainly learning a lot
Summary
Biosafety has to consider both the design of a gene transfer product and the possibility for this product to bypass the safety keys set up by the investigator to avoid the induction of unexpected deleterious effects. In this respect, in this two-part special issue T. Dishart et al (part II) highlight some very exciting advances in the field of cardiovascular disease It will be of interest over the few years to analyze whether clinical results will reach the expectations in this domain bearing in mind the lessons of gene therapy for cancer.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
